OBJECTIVES: To examine the independent association between five stages of activities of daily living (ADLs) and mortality after accounting for known diagnostic and sociodemographic risk factors. DESIGN: For five stages of ADLs (0 to IV), determined according to the severity and pattern of ADL limitations, unadjusted life expectancies and adjusted associations with mortality were estimated using a Cox proportional hazards regression model. SETTING: Community. PARTICIPANTS: Nine thousand four hundred forty-seven participants aged 70 and older from the second Longitudinal Study of Aging. MEASUREMENTS: One-, 5-, and 10-year survival and time to death. RESULTS: Median life expectancy was 10.6 years for participants with no ADL limitations and 6.5, 5.1, 3.8, and 1.6 years for those at ADL stages I, II, III, and IV, respectively. The sociodemographic- and diagnostic-adjusted hazard of death at 1 year was five times as great at stage IV as at stage 0 (hazard ratio = 5.6, 95% confidence interval = 3.8-8.3). The associations between ADL stage and mortality declined over time but remained statistically significant at 5 and 10 years. CONCLUSION: ADL stage continued to explain mortality risk after adjusting for known risk factors including advanced age, stroke, and cancer. ADL stages might aid clinical care planning and policy as a powerful prognostic indicator particularly of short-term mortality, improving on current ADL measures by profiling activity limitations of relevance to determining community support needs.
OBJECTIVES: To examine the independent association between five stages of activities of daily living (ADLs) and mortality after accounting for known diagnostic and sociodemographic risk factors. DESIGN: For five stages of ADLs (0 to IV), determined according to the severity and pattern of ADL limitations, unadjusted life expectancies and adjusted associations with mortality were estimated using a Cox proportional hazards regression model. SETTING: Community. PARTICIPANTS: Nine thousand four hundred forty-seven participants aged 70 and older from the second Longitudinal Study of Aging. MEASUREMENTS: One-, 5-, and 10-year survival and time to death. RESULTS: Median life expectancy was 10.6 years for participants with no ADL limitations and 6.5, 5.1, 3.8, and 1.6 years for those at ADL stages I, II, III, and IV, respectively. The sociodemographic- and diagnostic-adjusted hazard of death at 1 year was five times as great at stage IV as at stage 0 (hazard ratio = 5.6, 95% confidence interval = 3.8-8.3). The associations between ADL stage and mortality declined over time but remained statistically significant at 5 and 10 years. CONCLUSION: ADL stage continued to explain mortality risk after adjusting for known risk factors including advanced age, stroke, and cancer. ADL stages might aid clinical care planning and policy as a powerful prognostic indicator particularly of short-term mortality, improving on current ADL measures by profiling activity limitations of relevance to determining community support needs.
Authors: Margaret G Stineman; Dawei Xie; Qiang Pan; Jibby E Kurichi; Debra Saliba; Joel Streim Journal: J Am Geriatr Soc Date: 2011-03-01 Impact factor: 5.562
Authors: Margaret G Stineman; Richard N Ross; Roger Fiedler; Carl V Granger; Greg Maislin Journal: Arch Phys Med Rehabil Date: 2003-01 Impact factor: 3.966
Authors: Matteo Cesari; Graziano Onder; Valentina Zamboni; Todd Manini; Ronald I Shorr; Andrea Russo; Roberto Bernabei; Marco Pahor; Francesco Landi Journal: BMC Geriatr Date: 2008-12-22 Impact factor: 3.921
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Sean Hennessy; Jibby E Kurichi; Qiang Pan; Joel E Streim; Hillary R Bogner; Dawei Xie; Margaret G Stineman Journal: PM R Date: 2015-05-21 Impact factor: 2.298
Authors: Shuang He; Bruce A Craig; Huiping Xu; Kenneth E Covinsky; Eric Stallard; Joseph Thomas; Zach Hass; Laura P Sands Journal: J Gerontol A Biol Sci Med Sci Date: 2015-04-01 Impact factor: 6.053
Authors: P Su; H Ding; W Zhang; G Duan; Y Yang; J Long; L Du; C Xie; C Jin; C Hu; Z Sun; Z Duan; L Gong; W Tian Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Jibby E Kurichi; Hillary R Bogner; Joel E Streim; Dawei Xie; Pui L Kwong; Debra Saliba; Sean Hennessy Journal: Arch Gerontol Geriatr Date: 2017-08-24 Impact factor: 3.250
Authors: Ling Na; Qiang Pan; Dawei Xie; Jibby E Kurichi; Joel E Streim; Hillary R Bogner; Debra Saliba; Sean Hennessy Journal: PM R Date: 2016-09-21 Impact factor: 2.298